1-4 of 4
Kelly A. Smucker
Close
Sort by
Journal Articles

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew R. Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jessica MacMurray, Bonnie K. Harrington, Melanie E. Davis, Stefania Gobessi, Luca Laurenti, Betty Y. Chang, Joseph J. Buggy, Dimitar G. Efremov, John C. Byrd, Amy J. Johnson
Journal: Blood
Blood (2014) 123 (8): 1207–1213.
https://doi.org/10.1182/blood-2013-07-515361
Published: 2014
Includes: Supplemental data
Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua D. Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn M. Larkin, Matthew R. Stefanovski, Danielle L. Chappell, Frank W. Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Amy M. Lehman, Richard Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2013) 122 (15): 2539–2549.
https://doi.org/10.1182/blood-2013-06-507947
Published: 2013
Includes: Supplemental data
Journal Articles

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Jennifer A. Woyach, MD, Matthew R Stefanovski, B.S., Virginia Goettl, Amy S. Ruppert, MAS, Kelly A Smucker, Lisa L. Smith, Jason A Dubovsky, Ph.D, William H. Towns, Jessica MacMurray, Melanie E. Davis, Yicheng Mao, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, John C. Byrd, MD, Amy J Johnson, PhD
Journal: Blood
Blood (2012) 120 (21): 183.
https://doi.org/10.1182/blood.V120.21.183.183
Published: 2012
Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Jason A Dubovsky, Ph.D, Kyle A Beckwith, B.S., Jennifer A. Woyach, MD, Samantha M. Jaglowski, MD, MPH, Joshua Hessler, Betty Y. Chang, PhD, Karilyn Larkin, Matthew R Stefanovski, B.S., Frank W Frissora, M.S., Lisa L. Smith, Kelly A Smucker, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie A Andritsos, MD, Kami Maddocks, MD, Amy Lehman, Richard R. Furman, MD, Jeff Sharman, MD, Anjali Mishra, Ph.D., Michael A. Caligiuri, M.D., Joseph J. Buggy, PhD, Natarajan Muthusamy, DVM, Ph.D, Amy J Johnson, PhD, John C. Byrd, MD
Journal: Blood
Blood (2012) 120 (21): 775.
https://doi.org/10.1182/blood.V120.21.775.775
Published: 2012